The study team set out to develop, implement, and evaluate a PROMs module within the Australian Cystic Fibrosis Data Registry (ACFDR). They used a multi-phase mixed methods approach that combined co-design workshops with a pilot implementation and clinician evaluation. People with cystic fibrosis (pwCF), caregivers, and clinicians participated in co-design activities. These stakeholders identified preferred instruments and practical priorities for routine collection—electronic delivery, scheduled administration, and clear reporting of validated outcomes rose to the top.
Co-design produced two preferred instruments. The cohort and advisers recommended the CFQ-R and AWESCORE as the HRQoL measures to integrate into the registry. The authors reported that stakeholders viewed these instruments as relevant and feasible for routine collection within the ACFDR.
The PROMs module was implemented as a REDCap-based survey platform and piloted across 11 Australian cystic fibrosis centres. Investigators invited 1,052 participants during the pilot phase. Of those invited, 197 completed the questionnaires—an 18.7% response rate. The authors described the pilot as demonstrating feasibility of integration into existing registry infrastructure but also drew attention to the relatively low uptake.
Survey administration methods and recruitment processes were reported as part of the pilot, though the abstract does not provide detailed timing, frequency of follow-up reminders, or the demographic breakdown of responders versus non-responders. The source did not report additional operational metrics such as median completion time or platform technical issues.
Adults who completed the PROMs reported generally high overall HRQoL. The pilot data, however, revealed lower scores in specific domains: vitality, health perceptions, and treatment burden. The study team noted these areas as potential targets for clinical attention and quality-improvement initiatives.
The abstract does not include mean scores, standard deviations, or formal statistical comparisons. The authors therefore limited their reporting to domain-level observations rather than inferential conclusions about population-level changes.
Clinicians who evaluated the implementation supported collecting PROMs within the registry. They reported that registry-based PROMs could add patient-centred information that complements traditional clinical metrics. At the same time, the clinician survey identified practical concerns: survey fatigue among patients, low response rates during the pilot, time constraints for clinic staff, and questions about how PROMs data would be used in routine clinical workflows.
Clinicians also raised the need for clear, actionable reporting formats so that PROMs data can be interpreted efficiently during clinical encounters or used for quality improvement and benchmarking across centres.
Investigators flagged issues around data quality and representativeness. Low response rates during the pilot prompted concern that PROMs data captured in the registry might not reflect the broader population of pwCF in Australia. The study team reported clinician worries about potential bias introduced by selective response and the effect of survey fatigue on longitudinal data completeness.
The abstract lists several implementation barriers: maintaining engagement in the era of changing treatment paradigms (for example, widespread CFTR modulator use), reducing burden on respondents, and designing reporting that supports both clinical care and registry-level benchmarking.
The project received ethics approval from the Monash University Human Research Ethics Committee (Project ID 48261). The authors stated that written informed consent was obtained for the interview elements of the project. No competing interests were declared. The source notes that no individual-level data or images were shared in publication materials.
The authors concluded that integrating PROMs into the ACFDR is feasible and yields useful HRQoL information for pwCF, but they emphasized concrete next steps rather than broad generalities. Future implementation work should prioritise increasing participation and response rates, improving engagement strategies to address survey fatigue, and refining data reporting to enhance clinical utility, benchmarking, and quality improvement.
The abstract did not report detailed plans or timelines for scale-up, nor did it present subgroup analyses or longitudinal response patterns. Those operational details remain unanswered in the source and will need to be specified in subsequent implementation phases or full-text reporting.